We are always energized by medical congresses like ASCO – they are an opportunities to learn about the latest research developments and how companies and our peers are working to achieve better patient outcomes. It’s also an opportunity for us to learn more about what others are interested in learning, which is why we took a different approach for ASCO this year than what we’ve done in the past: we used social media to find out what you – the HCPs, patients, researchers and caregivers – want to hear about from us. The four polls issued from the @Novartis Twitter handle resulted in nearly 600 responses telling us what they were most interested in.
What we learned:
Not surprisingly, HCPs are most interested in hearing more about ongoing clinical trials. Our dedicated Novartis Oncology pipeline section, as well as the Novartis Institute for Biomedical Research website, are great resources that HCPs can take advantage of to learn more about the various pathways being targeted, diseases being investigated and compounds being tested here at Novartis.
Treatments and therapies are top of mind. Nearly half of respondents reported being most interested in hearing about new treatments at ASCO this year.
To get the scoop on the latest oncology research, treatments and news at ASCO and everywhere else, most turn to pharma resources, while others rely on their social circles and doctors. We encourage the oncology community to check out the various Novartis Oncology stories, which feature content on various disease areas, research, and more in the world of oncology.
Overall, the results of the polls provided us with some great insights into who makes up the ASCO audience, what people are interested in learning more about from Novartis Oncology and at future meetings, topics of interest and what resources are used by the community to stay up to date on oncology-related news.
We are excited about these learnings and look forward to translating them into ways we can better serve this community as a whole. Stay tuned for more social and digital insights.